Toolkit to Examine Lifelike Language v.2.0: Optimizing Speech Biomarkers of Neurodegeneration
; Ferrante, Franco Javier
; Pérez, Gonzalo Nicolas
; Ponferrada, Joaquín ; Sosa Welford, Alejandro ; Pelella, Nicolás ; Caccia, Ariel Matías ; Belloli, Laouen Mayal Louan
; Calcaterra, Cecilia ; González Santibáñez, Catalina ; Echegoyen, Raúl ; Cerrutti, Mariano Javier ; Jjohann, Fernando ; Hesse, Eugenia ; Carrillo, Facundo 
Otros responsables
Fecha
09/2024
Editorial
Karger
Revista
Dimentia And Geriatric Congnitive Disorders
Título del libro
Nombre del evento
Fecha del evento
Institución organizadora
ISSN
1420-8008
eISSN
1421-9824
ISBN
Idioma
Inglés
Tipo del evento
Clasificación temática
Palabras clave
Resumen
Introduction: The Toolkit to Examine Lifelike Language (TELL) is a web-based application providing speech biomarkers of neurodegeneration. After deployment of TELL v.1.0 in over 20 sites, we now introduce TELL v.2.0. Methods: First, we describe the app’s usability features, including functions for collecting and processing data onsite, offline, and via videoconference. Second, we summarize its clinical survey, tapping on relevant habits (e.g., smoking, sleep) alongside linguistic predictors of performance (language history, use, proficiency, and difficulties). Third, we detail TELL’s speech-based assessments, each combining strategic tasks and features capturing diagnostically relevant domains (motor function, semantic memory, episodic memory, and emotional processing). Fourth, we specify the app’s new data analysis, visualization, and download options. Finally, we list core challenges and opportunities for development. Results: Overall, TELL v.2.0 offers scalable, objective, and multidimensional insights for the field. Conclusion: Through its technical and scientific breakthroughs, this tool can enhance disease detection, phenotyping, and monitoring.
Colecciones
Aprobación
Revisión
Complementado por
Referenciado por
Licencia Creative Commons
Excepto donde se indique lo contrario, la licencia de este ítem se describe como by-nc-sa
